The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Aug. 18, 6:39 AM

Slide #24. Arcutis Biotherapeutics, Inc. Secondary Offering

Company: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Date announced: 8/2/2022
Shares Offered: 7,500,000
Date of Pricing: 8/2/2022
Price Per Share: $20.00
Secondary Offering Details: Arcutis Biotherapeutics, Inc. ("Arcutis") (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock. All of the shares in the offering are being sold by Arcutis. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering. In addition, Arcutis intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price. -updated 8/2- Arcutis Biotherapeutics, Inc. ("Arcutis") (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $20.00 per share, representing a premium to the closing price of $19.50 per share on August 2, 2022. In addition, Arcutis has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Arcutis from the offering are expected to be $150.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Arcutis, and assuming no exercise of the underwriters' option to purchase additional shares. Subject to the satisfaction of customary conditions, the offering is expected to close on August 5, 2022.

Arcutis Biotherapeutics is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with unmet medical needs. Co.'s product candidate, topical roflumilast cream, is used for plaque psoriasis, including intertriginous psoriasis, as well as atopic dermatitis. Co. is developing a topical foam formulation of roflumilast for the treatment of scalp psoriasis and seborrheic dermatitis; ARQ-252, a topical cream formulation of a small molecule inhibitor of Janus kinase type 1 for chronic hand eczema and vitiligo; and ARQ-255, an alternative topical formulation of ARQ-252 designed to reach into the skin in order to treat alopecia areata.

ARQT SEC Filing Email Alerts Service

Open the ARQT Page at The Online Investor »

Company Name: 
Arcutis Biotherapeutics Inc
Website: 
www.arcutis.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding ARQT: 
23
Total Market Value Held by ETFs: 
$96.84M
Total Market Capitalization: 
$1.27B
% of Market Cap. Held by ETFs: 
7.60%
 

Open the ARQT Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree ARQT Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.90 out of 4)
68th percentile
(ranked higher than approx. 68% of all stocks covered)

Analysts' Target Price:
ARQT Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.